Detalhe da pesquisa
1.
Safety of immune checkpoint inhibitors in patients aged over 80 years: a retrospective cohort study.
Cancer Immunol Immunother
; 73(7): 126, 2024 May 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38733406
2.
Investigation of a practical assessment index to capture the clinical presentation of cachexia in patients with lung cancer.
Jpn J Clin Oncol
; 54(3): 305-311, 2024 Mar 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38213068
3.
Pembrolizumab plus chemotherapy in Japanese patients with metastatic squamous non-small-cell lung cancer in KEYNOTE-407.
Cancer Sci
; 114(8): 3330-3341, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37183528
4.
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.
N Engl J Med
; 382(1): 41-50, 2020 01 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31751012
5.
Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trial.
BMC Cancer
; 23(1): 6, 2023 Jan 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36597021
6.
Phase I study of weekly nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer.
Invest New Drugs
; 40(1): 106-114, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34495421
7.
Massive digital gene expression analysis reveals different predictive profiles for immune checkpoint inhibitor therapy between adenocarcinoma and squamous cell carcinoma of advanced lung cancer.
BMC Cancer
; 22(1): 154, 2022 Feb 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35135489
8.
Pembrolizumab plus pemetrexed-platinum for metastatic nonsquamous non-small-cell lung cancer: KEYNOTE-189 Japan Study.
Cancer Sci
; 112(8): 3255-3265, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-34036692
9.
First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset.
Cancer Sci
; 112(12): 5000-5010, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34543477
10.
Phase I/II Study of Cisplatin plus Nab-Paclitaxel with Concurrent Thoracic Radiotherapy for Patients with Locally Advanced Non-Small Cell Lung Cancer.
Oncologist
; 26(1): 19-e52, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32918791
11.
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
N Engl J Med
; 378(2): 113-125, 2018 01 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-29151359
12.
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.
N Engl J Med
; 379(24): 2342-2350, 2018 12 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-30280658
13.
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
N Engl J Med
; 378(22): 2078-2092, 2018 May 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-29658856
14.
First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset.
Cancer Sci
; 111(12): 4480-4489, 2020 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-32926507
15.
Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
Cancer
; 126(22): 4867-4877, 2020 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32914866
16.
Evaluation of FOLFOX or CAPOX reintroduction with or without bevacizumab in relapsed colorectal cancer patients treated with oxaliplatin as adjuvant chemotherapy (REACT study).
Int J Clin Oncol
; 25(8): 1515-1522, 2020 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-32409917
17.
Genetic Profiling of Non-Small Cell Lung Cancer at Development of Resistance to First- or Second-Generation EGFR-TKIs by CAPP-Seq Analysis of Circulating Tumor DNA.
Oncologist
; 24(8): 1022-1026, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31023862
18.
Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset.
Jpn J Clin Oncol
; 49(1): 29-36, 2019 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30508196
19.
Exploration of resistance mechanisms for epidermal growth factor receptor-tyrosine kinase inhibitors based on plasma analysis by digital polymerase chain reaction and next-generation sequencing.
Cancer Sci
; 109(12): 3921-3933, 2018 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-30289575
20.
Phase 3 study of ceritinib vs chemotherapy in ALK-rearranged NSCLC patients previously treated with chemotherapy and crizotinib (ASCEND-5): Japanese subset.
Jpn J Clin Oncol
; 48(4): 367-375, 2018 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29474558